TRDA ENTRADA THERAPEUTICS
Permanent stock page ↗Health Care · Russell 2000
Next earnings: not announced yet
What 11 analyst firms say about ENTRADA THERAPEUTICS: their latest ratings, price targets and how far the stock is from them. How it works
Analyst window: Latest analyst report within last 1 year
Analyst view · last 1Y
10 rated views · 11 analyst/firm records · 11 firms
Radar score
- Russell 2000 · Top Picks · 6MNot scored · Fewer than 4 price targets in the last 6 months (3)
- Russell 2000 · Safest consensus · 6MNot scored · Fewer than 4 price targets in the last 6 months (3)
Recent analyst activity · last 90 days
Our tracked history has 6 reports on TRDA from 4 analyst firms in the last 90 days (11 firms in the past year).
Comparing each firm's latest target with its previous one: 1 left it unchanged.
No firm's latest available rating differs from its previous one.
Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.
| Firm | Analyst | Latest rating | Report date | Latest target (USD) |
|---|---|---|---|---|
| Cantor Fitzgerald | Yanni Souroutzidis | Buy | 1 Apr 2026 | — |
| Evercore ISI | Jonathan Miller | Buy | 7 Aug 2026 | 25.00 USD |
| Guggenheim | Debjit Chattopadhyay | Buy | 8 Jun 2026 | 17.00 USD |
| H.C. Wainwright | Raghuram Selvaraju | Hold | 19 Oct 2026 | — |
| Oppenheimer | Francois Brisebois | Buy | 6 Apr 2026 | 23.00 USD |
| Roth Capital | Boobalan Pachaiyappan | Buy | 16 Oct 2026 | 11.00 USD |
| TD Cowen | Joseph Thome | Buy | 15 Jun 2026 | — |
| UBS | Unnamed analyst | Hold | 19 Oct 2026 | — |
| Weiss Ratings | Unnamed analyst | — | 16 Oct 2026 | — |
| William Blair | Myles R Minter | Buy | 5 Aug 2026 | — |
| Data feed RESEARCH | Research Team | Hold | 15 Jun 2026 | — |
Partial coverage · checked 6 Nov (6 Nov 2026, 03:30 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.